Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
Conclusions
Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Clark, S. M., Clemmons, A. B., Schaack, L., Garren, J., DeRemer, D. L., Kota, V. K. Tags: Original Articles Source Type: research
More News: Cancer & Oncology | History of Medicine | Stem Cell Therapy | Stem Cells | Study | Transplants